We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $618B
1-Year Est. Return 30.34%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
988

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AWRE icon
7776
PUT
Aware
AWRE
$26M
-30,500
Closed -$142K
AXDX
7777
DELISTED
Accelerate Diagnostics
AXDX
-2,956
Closed -$693K
AXGN icon
7778
Axogen
AXGN
$2.67B
-27,231
Closed -$527K
AZZ icon
7779
CALL
AZZ Inc
AZZ
$4.55B
-7,600
Closed -$370K
BAK icon
7780
PUT
Braskem
BAK
$813M
-10,000
Closed -$267K
BBD icon
7781
Banco Bradesco
BBD
$34.3B
-23,390
Closed -$140K
BBDC icon
7782
CALL
Barings BDC
BBDC
$987M
-12,600
Closed -$180K
BBDO icon
7783
Banco Bradesco
BBDO
$34B
-17,394
Closed -$115K
BBN icon
7784
BlackRock Taxable Municipal Bond Trust
BBN
$984M
-17,669
Closed -$413K
BCLI
7785
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
-720
Closed -$44K
BCRX icon
7786
BioCryst Pharmaceuticals
BCRX
$2.71B
-1,395,547
Closed -$6.76M
BDRX
7787
Biodexa Pharmaceuticals
BDRX
$1.54M
0
-$18K
BF.A icon
7788
Brown-Forman Class A
BF.A
$13B
-4,548
Closed -$203K
BFOR icon
7789
Barron's 400 ETF
BFOR
$238M
-20,596
Closed -$204K
BFS
7790
Saul Centers
BFS
$850M
-5,758
Closed -$356K
BGI icon
7791
Birks Group
BGI
$6.5M
-16,108
Closed -$30K
BHB icon
7792
Bar Harbor Bankshares
BHB
$681M
-21,903
Closed -$687K
BHR
7793
PUT
Braemar Hotels & Resorts
BHR
$139M
-10,908
Closed -$103K
BIP icon
7794
Brookfield Infrastructure Partners
BIP
$18.2B
-8,272
Closed -$214K
BJRI icon
7795
PUT
BJ's Restaurants
BJRI
$1.48B
-16,300
Closed -$496K
BKE icon
7796
Buckle
BKE
$2.33B
-97,935
Closed -$1.93M
BKU icon
7797
PUT
Bankunited
BKU
$3.38B
-7,100
Closed -$253K
BLBD icon
7798
Blue Bird Corp
BLBD
$2.04B
-11,313
Closed -$233K
BLDP
7799
PUT
Ballard Power Systems
BLDP
$790M
-12,600
Closed -$59K
BLMN icon
7800
PUT
Bloomin' Brands
BLMN
$975M
-10,600
Closed -$187K

Similar funds

Ken Griffin's Q4 2017 Portfolio in Review

As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
  • Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.